Case report: Definitive therapy for local progression in patients with responding metastatic HER2-positive breast cancer
Abstract
BackgroundThe role of definitive locoregional treatment of the primary tumor in de novo metastatic breast cancer (MBC) remains controversial, with randomized trials largely demonstrating no survival benefit. In the era of effective HER2-targeted therapies, isolated progression at the primary tumor site in patients with otherwise well-controlled metastatic disease represents an emerging clinical scenario.MethodsWe conducted a retrospective case series of patients with HER2-positive MBC treated at our institution between January 2007 and June 2025 who developed isolated clinical local or locoregional progression and underwent definitive local therapy without modification of HER2-targeted systemic therapy. Patient and treatment characteristics were summarized descriptively. Outcomes of interest included duration of continued systemic therapy following local treatment with follow up until January 2026.ResultsNine patients were identified. Seven had liver metastases at diagnosis. All patients received taxane-based chemotherapy followed by maintenance trastuzumab with or without pertuzumab; seven achieved complete radiologic response. Six patients experienced local progression and three locoregional progression. Definitive local treatment included mastectomy in seven patients and lumpectomy in two. Three patients received radiotherapy. One surgical specimen contained DCIS only; all other invasive tumors retained HER2 positivity at progression. Following local therapy, patients continued first-line maintenance HER2-targeted treatment for a median of 45 months (range 11-156), including eight ongoing observations at last follow up. At last follow-up, all remained on the same systemic regimen except one who transitioned to TDxd after intracranial progression.ConclusionContinued use of the anti-HER2 backbone after local treatment was observed in this selected case series. Although these observations do not establish a causal benefit of local intervention, they support further studies to define the role of this approach in appropriately selected patients.
Related
- Positive psychological capital and social support mediate the association between perceived stress and fear of disease progression in postoperative lung cancer patients
- Positive islet autoantibodies confirm classical type 1 diabetes in patients treated as type 2 diabetes who have early progression to insulin
- Metastasis-directed therapy in addition to definitive locoregional radiotherapy for De novo metastatic nasopharyngeal carcinoma: a retrospective cohort study.
- Refusal of Definitive Care Among Patients With Salivary Gland Malignancies
- Prognostic Significance of the ESTRO/EORTC Classification of Oligometastatic Disease for Colorectal Cancer Patients With Uncommon Metastases Treated With Definitive Radiotherapy
BibTeX
@article{bernerwygoda2026case,
title = {{Case report: Definitive therapy for local progression in patients with responding metastatic HER2-positive breast cancer}},
author = {Yael Berner-Wygoda and Meredith Li and Mitchell Elliott and Jacqueline Savill and Neha Pathak and Michelle B. Nadler and Vikaash Kumar and Philippe L. Bedard and David W. Cescon and Eitan Amir},
journal = {Frontiers in Oncology},
year = {2026},
month = nov,
doi = {10.3389/fonc.2026.1833590},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1833590},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Case report: Definitive therapy for local progression in patients with responding metastatic HER2-positive breast cancer
AU - Yael Berner-Wygoda
AU - Meredith Li
AU - Mitchell Elliott
AU - Jacqueline Savill
AU - Neha Pathak
AU - Michelle B. Nadler
AU - Vikaash Kumar
AU - Philippe L. Bedard
AU - David W. Cescon
AU - Eitan Amir
PY - 2026
DA - 2026/11/09
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1833590
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1833590
AB - BackgroundThe role of definitive locoregional treatment of the primary tumor in de novo metastatic breast cancer (MBC) remains controversial, with randomized trials largely demonstrating no survival benefit. In the era of effective HER2-targeted therapies, isolated progression at the primary tumor site in patients with otherwise well-controlled metastatic disease represents an emerging clinical scenario.MethodsWe conducted a retrospective case series of patients with HER2-positive MBC treated at our institution between January 2007 and June 2025 who developed isolated clinical local or locoregional progression and underwent definitive local therapy without modification of HER2-targeted systemic therapy. Patient and treatment characteristics were summarized descriptively. Outcomes of interest included duration of continued systemic therapy following local treatment with follow up until January 2026.ResultsNine patients were identified. Seven had liver metastases at diagnosis. All patients received taxane-based chemotherapy followed by maintenance trastuzumab with or without pertuzumab; seven achieved complete radiologic response. Six patients experienced local progression and three locoregional progression. Definitive local treatment included mastectomy in seven patients and lumpectomy in two. Three patients received radiotherapy. One surgical specimen contained DCIS only; all other invasive tumors retained HER2 positivity at progression. Following local therapy, patients continued first-line maintenance HER2-targeted treatment for a median of 45 months (range 11-156), including eight ongoing observations at last follow up. At last follow-up, all remained on the same systemic regimen except one who transitioned to TDxd after intracranial progression.ConclusionContinued use of the anti-HER2 backbone after local treatment was observed in this selected case series. Although these observations do not establish a causal benefit of local intervention, they support further studies to define the role of this approach in appropriately selected patients.
SN - 2234-943X
ER -